Home/reMYND/Chris Freitag, MD
CF

Chris Freitag, MD

Clinical Advisor

reMYND

reMYND Pipeline

DrugIndicationPhase
REM392 (Alzheimer's Program)Alzheimer's DiseasePre-clinical
Huntington's ProgramHuntington's DiseasePre-clinical
Discovery ProgramAmyotrophic Lateral Sclerosis (ALS)Discovery